140 related articles for article (PubMed ID: 33627117)
21. Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009.
Wirtz VJ; Mol PG; Verdijk J; Vander Stichele RH; Taxis K
Trop Med Int Health; 2013 Apr; 18(4):416-25. PubMed ID: 23379471
[TBL] [Abstract][Full Text] [Related]
22. Implications of a defined daily dose fixed database for drug utilization research studies: The case of statins in Portugal.
Abrantes C; Tonin FS; Reis-Pardal J; Castel-Branco M; Furtado C; Figueiredo IV; Fernandez-Llimos F
Br J Clin Pharmacol; 2021 Sep; 87(9):3542-3549. PubMed ID: 33576512
[TBL] [Abstract][Full Text] [Related]
23. [Drug consumption in diabetes mellitus (III). Trends of hypoglycemic agents use and consumption in Tarragona, Catalonia, and Spain (1988- 1991). Group for the Study of Diabetes in Tarragona].
Costa B; Hernández JM
Med Clin (Barc); 1993 Apr; 100(15):571-5. PubMed ID: 8497145
[TBL] [Abstract][Full Text] [Related]
24. Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis.
Santa-Ana-Tellez Y; Mantel-Teeuwisse AK; Leufkens HG; Wirtz VJ
Health Policy Plan; 2016 Nov; 31(9):1291-6. PubMed ID: 27229872
[TBL] [Abstract][Full Text] [Related]
25. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
26. [Trends of antidiabetic drug prescriptions in Andalucia (1986-1994)].
Olveira G; Soriguer F; Vázquez F; González-Romero S; Ruiz de Adana S; Aguilar M
Aten Primaria; 1999; 24(3):145-51. PubMed ID: 10444868
[TBL] [Abstract][Full Text] [Related]
27. Prescribing of antidiabetic therapies in Ireland: 10-year trends 2003-2012.
Zaharan NL; Williams D; Bennett K
Ir J Med Sci; 2014 Jun; 183(2):311-8. PubMed ID: 24013870
[TBL] [Abstract][Full Text] [Related]
28. Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time.
Torre C; Guerreiro J; de Oliveira Martins S; Raposo JF; Martins AP; Leufkens H
Prim Care Diabetes; 2015 Dec; 9(6):482-9. PubMed ID: 25911273
[TBL] [Abstract][Full Text] [Related]
29. Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study.
Chan AYL; Yuen ASC; Tsai DHT; Lau WCY; Jani YH; Hsia Y; Osborn DPJ; Hayes JF; Besag FMC; Lai ECC; Wei L; Taxis K; Wong ICK; Man KKC
Nat Commun; 2023 Aug; 14(1):5005. PubMed ID: 37591833
[TBL] [Abstract][Full Text] [Related]
30. Prescriptions of antidepressants and anxiolytics in France 2012-2022 and changes with the COVID-19 pandemic: interrupted time series analysis.
De Bandt D; Haile SR; Devillers L; Bourrion B; Menges D
BMJ Ment Health; 2024 Feb; 27(1):. PubMed ID: 38413052
[TBL] [Abstract][Full Text] [Related]
31. Impact of a health alert and its implementation on flutamide prescriptions for women: an interrupted time series analysis.
Vázquez-Mourelle R; Carracedo-Martínez E; Figueiras A
BMC Health Serv Res; 2020 Jun; 20(1):597. PubMed ID: 32600343
[TBL] [Abstract][Full Text] [Related]
32. Recent trends in the prescribing of cholesterol lowering drugs in Australia. A report from the Drug Utilization Subcommittee of the Pharmaceutical Benefits Advisory Committee.
Henry DA; Cully LR; Grigson T; Lee C
Med J Aust; 1991 Sep; 155(5):332-6. PubMed ID: 1895979
[TBL] [Abstract][Full Text] [Related]
33. Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations.
Ponizovsky AM; Marom E; Weizman A; Schwartzberg E
Pharmacoepidemiol Drug Saf; 2018 May; 27(5):535-540. PubMed ID: 29488288
[TBL] [Abstract][Full Text] [Related]
34. Trends in the utilization of psychotropic medications in China from 2018 to 2021.
Zhang X; Hu X; Zhao Y; Lu CY; Nie X; Shi L
Front Pharmacol; 2022; 13():967826. PubMed ID: 36160455
[No Abstract] [Full Text] [Related]
35. Use of antidiabetic drugs in the U.S., 2003-2012.
Hampp C; Borders-Hemphill V; Moeny DG; Wysowski DK
Diabetes Care; 2014; 37(5):1367-74. PubMed ID: 24623020
[TBL] [Abstract][Full Text] [Related]
36. [Antidiabetic drugs and in-patient admissions attributable to diabetes in Portugal].
Gouveia M; Laires P; Borges M; Augusto M; Martins AP
Acta Med Port; 2012; 25(5):323-31. PubMed ID: 23211204
[TBL] [Abstract][Full Text] [Related]
37. Eleven-Year Trends in Lipid-Modifying Medicines Utilisation and Expenditure in a Low-Income Country: A Study from the Republic of Srpska, Bosnia and Herzegovina.
Kalinić D; Škrbić R; Vulić D; Stoisavljević-Šatara S; Stojaković N; Stojiljković MP; Marković-Peković V; Golić Jelić A; Pilipović-Broćeta N; Divac N
Clinicoecon Outcomes Res; 2023; 15():513-523. PubMed ID: 37405360
[TBL] [Abstract][Full Text] [Related]
38. Impact of rosiglitazone safety alerts on oral antidiabetic sales trends: a countrywide study in Portugal.
Herdeiro MT; Soares S; Silva T; Roque F; Figueiras A
Fundam Clin Pharmacol; 2016 Oct; 30(5):440-9. PubMed ID: 27259384
[TBL] [Abstract][Full Text] [Related]
39. Impact of removal and restriction of me-too medicines in a hospital drug formulary on in- and outpatient drug prescriptions: interrupted time series design with comparison group.
Vázquez-Mourelle R; Carracedo-Martínez E; Figueiras A
Implement Sci; 2019 Jul; 14(1):75. PubMed ID: 31340835
[TBL] [Abstract][Full Text] [Related]
40. [Prevalence and consumption of medication in diabetes mellitus in Madrid (1996-2002)].
Arrieta FJ; Calvo MJ; Peréz A; Saavedra P; Cordobés FJ; Cabral R; Arrieta JJ; Rovira A
Rev Clin Esp; 2006 Mar; 206(3):117-21. PubMed ID: 16597376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
